Literature DB >> 9361332

Haloperidol enhances latent inhibition in visual tasks in healthy people.

J H Williams1, N A Wellman, D P Geaney, J Feldon, P J Cowen, J N Rawlins.   

Abstract

We have previously shown that 0.5 mg haloperidol (i.v.) increased latent inhibition in one of two visual tasks. The present study analysed the effects of a higher dose of haloperidol (1.0 mg, i.v.) on latent inhibition in these two visual tasks in healthy volunteers in a randomised controlled trial. In the task where 0.5 mg haloperidol had enhanced latent inhibition, 1.0 mg had the same effect, thus replicating the previous result. In the task where 0.5 mg haloperidol had been ineffective, 1.0 mg haloperidol enhanced latent inhibition in high schizotypal subjects only. This indicates that subjects with higher schizotypy scores are more sensitive to dopamine blockade. A comparison of the results from the studies at the two different doses suggests a dose dependence of haloperidol's effects on latent inhibition that parallels results from animal work.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361332     DOI: 10.1007/s002130050400

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

3.  Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Authors:  Anne Schmechtig; Jane Lees; Lois Grayson; Kevin J Craig; Rukiya Dadhiwala; Gerard R Dawson; J F William Deakin; Colin T Dourish; Ivan Koychev; Katrina McMullen; Ellen M Migo; Charlotte Perry; Lawrence Wilkinson; Robin Morris; Steve C R Williams; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2013-02-22       Impact factor: 4.530

4.  Levodopa reverses gait asymmetries related to anhedonia and magical ideation.

Authors:  Christine Mohr; Theodor Landis; H Stefan Bracha; Marc Fathi; Peter Brugger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 5.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

6.  Catecholaminergic depletion within the prelimbic medial prefrontal cortex enhances latent inhibition.

Authors:  A J D Nelson; K E Thur; C A Marsden; H J Cassaday
Journal:  Neuroscience       Date:  2010-07-07       Impact factor: 3.590

7.  A pre-clinical study showing how dopaminergic drugs administered during pre-exposure can impair or facilitate latent inhibition.

Authors:  N A Schmajuk; J A Gray; J A Larrauri
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

8.  Reduced dopamine function within the medial shell of the nucleus accumbens enhances latent inhibition.

Authors:  A J D Nelson; K E Thur; R R Horsley; C Spicer; C A Marsden; H J Cassaday
Journal:  Pharmacol Biochem Behav       Date:  2010-12-10       Impact factor: 3.533

9.  Opposing effects of 5,7-DHT lesions to the core and shell of the nucleus accumbens on the processing of irrelevant stimuli.

Authors:  Andrew J D Nelson; Karen E Thur; Charles A Marsden; Helen J Cassaday
Journal:  Int J Neuropsychopharmacol       Date:  2011-04-18       Impact factor: 5.176

Review 10.  An Overview of the Association between Schizotypy and Dopamine.

Authors:  Christine Mohr; Ulrich Ettinger
Journal:  Front Psychiatry       Date:  2014-12-19       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.